抗GAD抗体陽性C型慢性肝炎に対するインターフェロン療法の検討

概要

論文の詳細を見る
Development of type 1 diabetes mellitus (T1DM) has been reported in patients receiving interferon (IFN) therapy for hepatitis C virus (HCV) infection. We studied two patients with chronic HCV infection who had an anti-glutamic acid decarboxylase antibody (GAD-ab) before IFN therapy. Their blood sugar and GAD-ab levels were monitored during IFN therapy. Case 1 was a 61-year-old man with 16.9 U/mL of GAD-ab. The GAD-ab level decreased during IFN therapy, but remained positive. Case 2 was a 65-year-old woman with 2.0 U/mL of GAD-ab. Her GAD-ab level increased during IFN therapy, but decreased after withdrawal of IFN. Insulin secretion in both patients was kept within physiologically normal range during IFN therapy, and the treatment was completed without developing T1DM in both cases.
社団法人　日本肝臓学会の論文
2008-03-25